CCCS invites feedback over merger concerns on PAH deals
Response will help watchdog assess if planned consolidation of two clinical laboratories will reduce competition
Add BT as a preferred source
Fiona Lam
Singapore
THE Competition and Consumer Commission of Singapore (CCCS) is inviting public feedback on the two-year commitments proposed by Pathology Asia Holdings (PAH) to address competition concerns in its planned merger of two private clinical laboratories.
PAH, a unit of private equity giant TPG Capital Asia, intends to integrate the businesses of the two labs - Innovative Diagnostics and Quest Laboratories - after acquiring them last year.
TRENDING NOW
Jumbo Seafood to close flagship East Coast Seafood Centre outlet on Sep 30
Shanda co-founder sells Tanglin Hill bungalow for S$76 million
Johor property old hand KSL readies family handover amid market boom
Yeo’s, Tiger Beer and now Gardenia – flight of food manufacturing from Singapore might be just as planned
